ICD-11 · 6C42.21

Synthetic cannabinoid dependence, early full remission

After a diagnosis of synthetic cannabinoid dependence, and often following a treatment episode or other intervention (including self-help intervention), the individual has been abstinent from synthetic cannabinoid use during a period lasting between 1 and 12 months.

ICD-11 diagnostic criteria

How to recognise

In the ICD-11 framework, the core symptoms taken into account when recognising Synthetic cannabinoid dependence, early full remission are:

Differential diagnosis

When diagnosing Synthetic cannabinoid dependence, early full remission, the following ICD-11 disorders should be considered in the differential diagnosis:

Frequently asked questions

How is Synthetic cannabinoid dependence, early full remission diagnosed according to ICD-11?

According to ICD-11, the diagnostic criteria for Synthetic cannabinoid dependence, early full remission (6C42.21) include: wcześniej rozpoznane uzależnienie od syntetycznych kannabinoidów; brak używania substancji przez okres od 1 do 12 miesięcy.

What disorders are in the differential diagnosis of Synthetic cannabinoid dependence, early full remission?

The differential diagnosis of Synthetic cannabinoid dependence, early full remission (6C42.21) includes: Epizod szkodliwego używania syntetycznych kannabinoidów (6C42.0), Szkodliwy wzorzec używania syntetycznych kannabinoidów (6C42.1).

WHO ICD-11 source

View this entry in the official WHO ICD-11 browser: 6C42.21 – WHO ICD-11

Open in interactive browser →
Source: WHO ICD-11 (chapter 6 – Mental, behavioral and neurodevelopmental disorders). Used under CC BY-ND 3.0 IGO. ICD Diagnostica is not affiliated with or endorsed by WHO. Informational use only – does not replace clinical judgment.